Aligos Therapeutics Announces Six Preclinical Presentations at 2025 International HBV Meeting: Novel Approaches and Molecular Strategies to Advance Liver and Viral Diseases.

Aligos Therapeutics announced six preclinical presentations at the 2025 International HBV Meeting. The presentations cover novel approaches, molecular strategies, and insights into ALG-000184's mechanism of action. The company also showcased a new strategy to potentially cure hepatitis delta virus infection using a proprietary antisense oligonucleotide approach.

Aligos Therapeutics (Nasdaq: ALGS) has announced six preclinical presentations at the 2025 International HBV Meeting in Berlin, Germany. The presentations, which include three oral presentations and three poster presentations, showcase the company's ongoing research in liver and viral diseases, particularly focusing on ALG-000184 and a new antisense oligonucleotide (ASO) approach for hepatitis delta virus (HDV) treatment [1].

The presentations highlight Aligos' commitment to advancing next-generation therapies for liver and viral diseases. Key highlights include the first presentation of ALG-000184's direct effects in reducing HBV cccDNA in preclinical settings, supporting clinical observations of HBV antigen reductions in patients [1]. Additionally, the company is expanding its pipeline with an ASO program for HDV treatment, targeting viral genome destruction as a potential cure strategy for HDV coinfection, which typically leads to more rapid disease progression [1].

The presentations will cover a range of topics, including novel approaches, molecular strategies, and insights into the mechanisms of action of ALG-000184. The oral presentations will be held on September 11, 2025, at 10:30 AM CET, while the poster presentations will be held on September 8 and 10, 2025, at various times [1].

The presentations can be found on the Posters & Presentations section of the Aligos website after the live event. For more information, please visit or follow Aligos on LinkedIn or X.

References:
[1] https://www.stocktitan.net/news/ALGS/aligos-therapeutics-announces-six-preclinical-presentations-at-the-lsn99cubm1v9.html